Related Experiment Videos
Regulation of insulin-like growth factors by antiestrogen
R Winston1, P C Kao, D T Kiang
1Department of Medicine, University of Minnesota Medical School, Minneapolis 55455.
Abstract:
Insulin-like growth factors are potent mitogens for breast cancer cell proliferation. This effect is modulated by the circulatory and extracellular IGFBPs as well as by the affinity of ligand binding receptors on the target cells. Antiestrogens have been shown to reduce both circulatory and microenvironmental IGF levels and thus suppress the IGF-I-induced growth of both ER-positive and ER-negative breast cancer cells. However, the effects of antiestrogens in down regulation of type I IGF receptor and in altering the autophosphorylation tyrosine kinase activity of EGF receptors are mainly observed in ER-positive cells. Furthermore, alteration of IGFBP by antiestrogens such as a marked increase of IGFBP-I production have been shown to inhibit the proliferative effect of IGF-I on ER-positive, but stimulate this effect, on ER-negative cells. Such differential effects from IGF receptor and IGFBP may explain the clinical outcome that tumor regression from antiestrogens is mainly observed in ER-positive type. This assumption based on IGF regulation alone is certainly an oversimplistic view amid the complexity of autocrine, paracrine, and endocrine functions.
Insights
Antiestrogens suppress breast cancer growth by lowering insulin-like growth factors (IGFs). Differential effects on IGF receptors and binding proteins may explain why these drugs are more effective in ER-positive breast cancers.
Area of Science:
- Endocrinology
- Cancer Biology
- Molecular Oncology
Background:
- Insulin-like growth factors (IGFs) are key drivers of breast cancer cell proliferation.
- IGF effects are modulated by IGF-binding proteins (IGFBPs) and receptor affinity.
- Antiestrogens can reduce IGF levels, impacting breast cancer growth.
Purpose of the Study:
- To investigate the differential effects of antiestrogens on IGF signaling pathways in ER-positive and ER-negative breast cancer cells.
- To explore how antiestrogens modulate IGF type I receptor and EGF receptor activity.
- To understand the role of IGFBPs in mediating antiestrogen effects on breast cancer proliferation.
Main Methods:
- Analysis of antiestrogen effects on IGF levels.
- Assessment of type I IGF receptor and EGF receptor activity.
- Evaluation of IGFBP production and its impact on IGF-I-induced proliferation.
Main Results:
- Antiestrogens reduce circulatory and microenvironmental IGF levels, suppressing proliferation in both ER-positive and ER-negative cells.
- Downregulation of type I IGF receptor and altered EGF receptor activity by antiestrogens are mainly observed in ER-positive cells.
- Antiestrogens increase IGFBP-I production, inhibiting IGF-I effects in ER-positive cells but stimulating them in ER-negative cells.
Conclusions:
- Differential modulation of IGF receptors and IGFBPs by antiestrogens may explain their selective efficacy in ER-positive breast cancer.
- The complex interplay of autocrine, paracrine, and endocrine IGF functions needs further investigation.
- IGF signaling represents a potential therapeutic target in breast cancer treatment.